How axatilimab affects skin in chronic graft-versus-host disease
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study is testing how well a medicine called axatilimab works on skin symptoms caused by chronic graft-versus-host disease (cGVHD), a complication after a stem cell or bone marrow transplant. Researchers will compare people who take axatilimab as part of their regular care with those who don't, and they will look at both skin health and skin biopsy samples to see what changes occur.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have chronic graft-versus-host disease (cGVHD) that affects your skin
- You are either planning to start the medicine axatilimab as part of your regular care, or you are not planning to take it (you can join either group)
- You can have a skin biopsy (a small sample of skin taken for testing)
- You do not have any active infections that are not under control
- You do not have any condition (like very low platelets) that would make a skin biopsy risky
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (axatilimab) combined with a light-based blood treatment (ECP) for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It's for those who have already tried at least 2 other treatments or need high doses of steroids.
This study follows patients who have had a stem cell transplant and developed chronic graft-versus-host disease (a condition where transplanted cells attack the body). Researchers will track your symptoms and collect blood samples to understand what affects how well patients do over time.
This trial tests an experimental drug called Iguratimod for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It aims to see if the drug can safely control cGVHD symptoms when other treatments haven't worked well enough.
This trial tests an experimental drug (ABSK021) for people with chronic graft-versus-host disease (cGvHD) after a stem cell transplant. It may help if other treatments haven't worked well enough.
This study tests a new drug called axatilimab for people with a specific type of chronic graft-versus-host disease (cGVHD) that causes hardening or thickening of the skin or joints. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack your body. The study aims to see if axatilimab can improve these sclerotic symptoms. If you have this condition and it was recently diagnosed (within the last year), you might qualify to participate.
This trial tests a new drug called axatilimab to help patients whose chronic graft-versus-host disease (a condition where transplanted immune cells attack the body) isn't responding well to standard treatments. Researchers want to find the right dose and see if it can improve symptoms and quality of life.
Hear when a new cGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.